IOSP INNOSPEC INC.
Chemicals & Allied Products · Nasdaq · SEC CIK 1054905 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY2,749.1%
TTM EPS YoY14,250.0%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR3.4%
Margins
Gross margin27.7%
Operating margin8.8%
Net margin7.5%
FCF margin2.5%
EBITDA margin10.9%
Returns
ROE10.5%
ROA7.7%
ROIC (approx.)12.4%
Asset turnover1.03x
Leverage & solvency
Liabilities / assets25.7%
Debt / equity0.00x
Current ratio2.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio2.0%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $473.60M | $491.40M | $453.20M | $455.60M | $441.90M | $439.70M | $440.80M | $466.80M |
| Cost of revenue | $344.50M | $353.10M | $329.70M | $328.20M | $325.20M | $316.50M | $315.70M | $330.60M |
| Gross profit | $129.10M | $138.30M | $123.50M | $127.40M | $116.70M | $123.20M | $125.10M | $136.20M |
| R&D expense | $16.80M | $14.20M | $13.20M | $11.00M | $13.70M | $13.60M | $12.70M | $14.90M |
| SG&A expense | $71.70M | $84.30M | $78.50M | $69.30M | $71.90M | $74.60M | $69.30M | $78.90M |
| Operating income | $41.70M | $39.70M | $36.50M | $46.80M | $5.90M | $34.30M | $42.50M | $41.10M |
| Pretax income | $42.60M | $41.60M | $39.90M | $49.30M | $11.30M | $32.30M | $45.20M | -$102.60M |
| Income tax | $11.00M | $10.40M | $9.10M | $2.90M | -$1.40M | $8.40M | $11.60M | -$32.20M |
| Net income | $31.80M | $30.80M | $30.40M | $47.40M | $12.90M | $23.50M | $32.80M | -$74.50M |
| EBITDA | $51.30M | $49.70M | $46.40M | $56.20M | $18.10M | $45.40M | $53.40M | $52.00M |
| EPS (basic) | 1.29 | 1.25 | 1.23 | — | 0.52 | 0.94 | 1.31 | — |
| EPS (diluted) | 1.29 | 1.25 | 1.22 | — | 0.52 | 0.94 | 1.31 | — |
| Dividends declared per share | 0.00 | 0.84 | — | 0.87 | 0.00 | 0.76 | — | 0.79 |
| Weighted avg. shares (diluted) | 24.74M | 24.71M | 24.84M | — | 24.91M | 25.04M | 25.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $251.90M | $250.20M | $289.10M | $292.50M | $270.80M | $266.60M | $299.80M | $289.20M |
| Receivables | $395.60M | $408.60M | $354.20M | $342.30M | $349.50M | $336.10M | $343.50M | $341.70M |
| Inventory | $361.80M | $337.30M | $321.50M | $329.30M | $345.20M | $336.80M | $315.40M | $301.00M |
| Current assets | $1.03B | $1.02B | $999.10M | $1.00B | $988.80M | $969.70M | $977.10M | $956.60M |
| PP&E, net | $300.20M | $293.30M | $285.70M | $286.10M | $278.60M | $295.80M | $277.10M | $269.70M |
| Goodwill | $397.40M | $398.20M | $399.10M | $399.00M | $399.80M | $397.60M | $388.40M | $382.50M |
| Intangibles | $62.50M | $65.30M | $68.90M | $67.70M | $63.30M | $78.30M | $72.80M | $65.40M |
| Total assets | $1.86B | $1.85B | $1.82B | $1.83B | $1.80B | $1.81B | $1.77B | $1.73B |
| Current liabilities | $351.20M | $368.10M | $334.80M | $360.10M | $356.10M | $337.40M | $357.60M | $371.40M |
| Total liabilities | $476.30M | $495.20M | $467.60M | $499.50M | $496.50M | $504.60M | $508.90M | $518.60M |
| Shareholders' equity | $1.37B | $1.34B | $1.34B | $1.33B | $1.30B | $1.30B | $1.26B | $1.21B |
| Cash flow statement | ||||||||
| Operating cash flow | $17.40M | $7.20M | $17.60M | $61.40M | $39.10M | $9.30M | $28.30M | $25.70M |
| Capital expenditure | $15.80M | $17.70M | $8.90M | $14.60M | $14.30M | $13.00M | $8.40M | $12.10M |
| Free cash flow | $1.60M | -$10.50M | $8.70M | $46.80M | $24.80M | -$3.70M | $19.90M | $13.60M |
| Investing cash flow | -$15.60M | -$16.50M | -$13.70M | -$19.20M | -$24.20M | -$16.20M | -$15.50M | -$20.60M |
| Financing cash flow | $100,000 | -$29.50M | -$6.60M | -$20.60M | -$10.60M | -$28.70M | -$3.80M | -$17.80M |
| Depreciation & amortization | $9.60M | $10.00M | $9.90M | $9.40M | $12.20M | $11.10M | $10.90M | $10.90M |
| Stock-based compensation | $3.70M | $4.90M | $1.60M | $3.10M | $1.60M | $2.50M | $1.90M | $2.10M |
| Dividends paid | $0 | — | — | $21.60M | $0 | — | — | $19.80M |
| Share buybacks | $0 | $6.40M | $7.10M | $0 | $10.60M | $8.50M | $4.80M | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.